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Contributions of function-altering variants in genes implicated in 73	
pubertal timing and body mass for self-limited delayed puberty 74	
  75	
Abstract  76	
Context: Self-limited delayed puberty (DP) is often associated with delay in 77	
physical maturation, but whilst highly heritable the causal genetic factors 78	
remain elusive. Genome-wide association studies of the timing of puberty 79	
have identified multiple loci for age of menarche (AAM) in females and voice 80	
break in males, particularly in pathways controlling energy balance.  81	
Objective/Main outcome measures: We aimed to assess the contribution of 82	
rare variants in such genes to the phenotype of familial DP.   83	
Design/Patients: We performed whole exome sequencing (WES) in 67 84	
pedigrees (125 individuals with DP and 35 unaffected controls) from our 85	
unique cohort of familial self-limited DP. Using a WES filtering pipeline one 86	
candidate gene (FTO) was identified. In silico, in vitro and mouse model 87	
studies were performed to investigate the pathogenicity of FTO variants and 88	
timing of puberty in FTO+/- mice. 89	
Results: We identified potentially pathogenic, rare variants in genes in linkage 90	
disequilibrium with GWAS of AAM loci in 283 genes. Of these, 5 genes were 91	
implicated in the control of body mass. After filtering for segregation with trait 92	
one candidate, FTO, was retained. Two FTO variants, found in 14 affected 93	
individuals from 3 families, were also associated with leanness in these DP 94	
patients. One variant (p.Leu44Val) demonstrated altered demethylation 95	
activity of the mutant protein in vitro. Fto+/- mice displayed a significantly 96	
delayed timing of pubertal onset (p <0.05). 97	
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Conclusions: Mutations in genes implicated in body mass and timing of 98	
puberty in the general population may contribute to the pathogenesis of self-99	
limited DP.   100	
  101	
Introduction  102	
Puberty is the maturational process of the reproductive endocrine system that 103	
results in adult height and body proportion, in addition to the capacity to 104	
reproduce. A minimum level of energy availability is required for the onset of 105	
puberty, whilst increased fat mass has been shown to be associated with 106	
precocious onset of puberty (1,2). However, a role for genes connected with 107	
regulation of body mass have not been clearly demonstrated in pubertal 108	
timing.   109	
The existence of genetic heterogeneity in pubertal timing is supported by 110	
several large genome wide association studies (GWAS) of the age of 111	
menarche (AAM) (3-5). Evidence (P< 5 x 10-8) for 123 signals at 106 genomic 112	
loci has been identified. Many of these loci were associated with Tanner 113	
staging in both sexes, suggesting this data is applicable to both men and 114	
women(6,7).  115	
The first of many GWAS loci associated with AAM was the developmental 116	
gene LIN28B (3,8). Additional signals in genes involved in energy homeostasis 117	
and growth have been found near LEPR-LEPROT, which encodes the leptin 118	
receptor. Leptin (a key regulator of body mass) is an important permissive 119	
signal for the onset of puberty (9). In addition to leptin signaling, overlap with 120	
several genes implicated in body mass index was found, including FTO, 121	
SEC16B, TMEM18, and NEGR1 (Supplementary Table 1) (5).  Whether such 122	
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genes may regulate pubertal timing exclusively via impact on fat mass or via 123	
other BMI-independent mechanisms is unknown (10).   124	
Disordered pubertal timing affects up to 5% of adolescents and is associated 125	
with adverse health and psychosocial outcomes (11-14). Self-limited delayed 126	
puberty (DP) represents the extreme end of normal pubertal timing, and is 127	
defined as the absence of testicular enlargement in boys or breast 128	
development in girls at an age that is 2 to 2.5 standard deviations (SD) later 129	
than the population mean3. DP may be an isolated feature of the condition or 130	
be associated with constitutional delay in growth that can manifest from 131	
early childhood.  132	
DP segregates within families, usually with an autosomal dominant pattern of 133	
inheritance (15,16). Despite strong heritability in most cases the genetic basis of 134	
DP remains elusive (17) (18).  Moreover, the relevance of genetic factors 135	
influencing timing of puberty in the general population to patients with extreme 136	
pubertal delay has not been explored. Given the importance of energy 137	
balance for reproductive health, genes identified by AAM GWAS that relate to 138	
energy homeostasis are of particular interest. Our multi-generational 139	
DP families provide a highly valuable resource to investigate these candidate 140	
genes in familial DP. 141	
  142	
Materials and Methods   143	
Patients  144	
The patients selected for this study are taken from a previously described, 145	
accurately phenotyped and characterized, Finnish DP patient cohort(19). 146	
Diagnosis is based on objective evidence of a delayed pubertal growth spurt 147	
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rather than self-recall. Patients referred with DP to specialist paediatric care in 148	
central and southern Finland (1982-2004) were identified. All patients (n=492) 149	
met the diagnostic criteria for self-limited DP, defined as the onset of Tanner 150	
genital stage II (testicular volume >3 ml) >13.5yr in boys or Tanner breast 151	
stage II >13.0yr in girls (i.e. two SD later than average pubertal development) 152	
(18,20). Pubertal growth spurt in probands was more than 2 SD later than 153	
average: age at acceleration of pubertal growth (take-off) beyond 13.8 and 154	
12.2 yr and age at peak height velocity (PHV) later than 15.6 and 13.7 yr in 155	
males and females, respectively (21). 156	
 Chronic illness and undernutrition was excluded by medical history, clinical 157	
examination, and routine laboratory tests. HH, if suspected, was excluded by 158	
spontaneous pubertal development at follow-up. In the 50% of patients who 159	
choose to have pubertal induction via the use of exogenous sex steroids, all 160	
patients were followed up until the point of full pubertal development (Tanner 161	
stage G4+ or B4+) to ensure development did not arrest off treatment.  162	
Families of the DP patients were invited to participate, with information about 163	
medical history and pubertal timing obtained by structured interviews and from 164	
archived height records. The criteria for DP in probands’ family members were 165	
one or more of: 1) age at takeoff or 2) PHV occurring 1.5 SD beyond the 166	
mean, i.e. age at takeoff exceeding 12.9 and 11.3 yr, or age 167	
at PHV exceeding 14.8 and 12.8 yr in males and females, or 3) age at 168	
attaining adult height more than 18 or 16 yr, in males and females, 169	
respectively (19).  Previous linkage analysis from this cohort did not find 170	
evidence for linked families sharing chromosomal segments identical by 171	
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descent, suggesting a founder effect is unlikely to be responsible for this 172	
phenotype (19). 173	
Written informed consent was obtained from all participants. The study 174	
protocol was approved by the Ethics Committee for Pediatrics, Adolescent 175	
Medicine and Psychiatry, Hospital District of Helsinki and Uusimaa (extended 176	
to encompass Kuopio, Tampere and Turku University Hospitals) 177	
(570/E7/2003). UK ethical approval was granted by the London-Chelsea 178	
NRES committee (13/LO/0257). The study was conducted in accordance with 179	
the guidelines of The Declaration of Helsinki.  180	
Genetic Analysis   181	
Genetic analysis was performed in 160 individuals from the 67 most extensive 182	
families from our cohort with DP. These included 67 probands (male n=57, 183	
female n=10), 58 affected family members (male n=36, female n=22) and 35 184	
unaffected family members (male, n=13, female n=22). Whole exome 185	
sequencing (WES) was performed on DNA extracted from peripheral blood 186	
leukocytes. Variants were analyzed and filtered for potential causal variants in 187	
Ingenuity Variant Analysis (Qiagen) using filters for quality control, predicted 188	
functional annotation, minor allele frequency (MAF), and GWAS relevance 189	
(Figure 1). GWAS relevance filtering allowed identification of those remaining 190	
variants that lay within genes in linkage disequilibrium with 106 GWAS loci 191	
associated with AAM (n=760) (5). Filters for genes implicated in body mass 192	
regulation were applied using a biological context filter with pathway analysis. 193	
Variants were filtered for segregation with trait in family members using 194	
conventional Sanger sequencing.  195	
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Targeted exome sequencing using a Fluidigm array of the remaining 196	
candidate gene identified post-filtering was then performed in a further 42 197	
cohort families (288 individuals, 178 with DP; male=106, female=69 and 110 198	
controls; male=55, female=58, Figure 1). Whole gene rare variant burden 199	
testing was performed post sequencing.  200	
Growth Pattern Analysis  201	
The pattern of prepubertal growth in the individuals carrying FTO variants was 202	
analyzed by using five screening parameters: 1) height for age standard 203	
deviation score (HSDS); 2) body mass index (BMI; calculated as weight in 204	
kilograms divided by height in meters squared) for age SDS (BMI SDS); 3) 205	
HSDS distance from target height (TH) (TH formula = 0.791 × mean parental 206	
height SDS − 0.147 for girls and 0.886 × mean parental height SDS – 0.071 for 207	
boys; 4) change in height SDS (∆HSDS); 5) change in BMI SDS (∆BMI SDS) 208	
across time with free age intervals. The calculations of the age-specific and 209	
sex-specific normal values for ∆HSDS and ∆BMI SDS were based on 210	
longitudinal reference measurements (22). Normality of linear growth was 211	
tested by using auxological screening rules based on data from >70,000 212	
healthy Finnish children(23).  213	
In silico Analysis  214	
The FTO experimentally solved structure (PDB identifier: 4cxx) was used to 215	
study the structural effect of FTO variants. The following interactions involved 216	
in protein stability were considered: i) salt bridges; ii) hydrogen bonds (H-217	
bond); and iii) disulphide bridge (S-S bridge). N-glycosylation sites were 218	
determined based on the consensus sequence Asn-X-Thr/Ser (X= any amino 219	
	 10	
acid, except proline). The DSSP program was used to calculate surface 220	
accessibility and Disopred3 (24) to predict disordered protein regions.    221	
Functional Annotation of FTO mutant proteins  222	
Cloning of wild-type human FTO cDNA into pET302/NT-His has been 223	
described previously (25). The p.Leu44Val and p.Ala163Thr point mutations 224	
were introduced using PCR-mediated mutagenesis (Quickchange II, 225	
Agilent Technoligies) using primers FTO_L44V FOR: 5'-226	
GAATTCTATCAGCAGTGGCAGGTGAAATATCCTAAACTAATTCT-3', REV: 227	
5'-AGAATTAGTTTAGGATATTTCACCTGCCACTGCTGATAGAATTC-3' and 228	
FTO_A163T FOR: 5'-CACAGCATCCTCATTAGTCTTCTCTTTGGCAGCAA-229	
3', REV: 5'-TTGCTGCCAAAGAGAAGACTAATGAGGATGCTGTG-3' and 230	
verified by sequencing. An RNase-cleavage assay (26) was used to measure 231	
the demethylation activity of FTO on 3-methyl-uridine (3-meU). Recombinant 232	
wild-type and mutant FTO expression plasmids were transformed 233	
into Escherichia coli BL21-Gold (DE3) (Stratagene) and cultured in LB broth 234	
and 50 μg/ml carbenicillin. Expression of the cloned gene was induced by the 235	
addition of IPTG (isopropyl-β-D-1-thiogalactopyranoside) at 1 mM final 236	
concentration at 15◦C for 4 h. The cells were harvested and 237	
pellets resuspended in lysis buffer [50 mM HEPES-KOH (pH 8.0), 2 mM 2-238	
mercaptoethanol, 5% glycerol and 300mM NaCl] before digestion with 239	
lysozyme (1 mg/ml). The cleared lysate was supplemented with imidazole 240	
(final concentration 10 mM) before mixing with 1 ml of pre- washed Ni-NTA 241	
(Ni2+-nitrilotriacetate) beads (Qiagen). After binding for 1 h in the cold, the 242	
mixture was washed with lysis buffer supplemented with increasing 243	
concentrations of imidazole. FTO was eluted with 2 ml of lysis buffer 244	
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containing 250 mM imidazole. The eluate was concentrated with a 30 kDa 245	
molecular-mass cut-off concentrator (Sartorius Stedim) with buffer changing 246	
to 20 mM HEPES-KOH (pH 8), 5 % glycerol and 50 mM NaCl. Purified 247	
proteins were snap-frozen and stored at −80◦C. Protein purity was estimated 248	
by Commassie Blue staining after resolving by SDS/PAGE (4–12 % gradient 249	
gels; Invitrogen).  250	
Dose response of FTO on 3-meU demethylation: Recombinant FTO proteins 251	
were assayed as previously described (26). Each protein, at different protein 252	
concentrations from 0 -1000 nM, was assayed in a reaction containing 100 253	
nM substrate, 75 μM Fe(NH4)2(SO4)2, 300 μM 2-OG, 2 mM ascorbate, 254	
50 μg/ml BSA and 62.5 μg/μl of RNase A in 50 mM Tris/HCl buffer at pH 7.0. 255	
Samples were prepared in duplicate in a dark flat-bottomed 96-well plate and 256	
the FAM (6-carboxyfluorescein) emission was measured for 30 min at a 257	
wavelength of 520 nm with excitation at 485 nm. The measurement was 258	
performed at room temperature (25◦C) using a microplate reader [Infinite 259	
M1000, Tecan].  Wild type (WT) FTO protein and catalytically inactive mutant 260	
p.Arg316Gln (R316Q) served as positive and negative controls respectively.  261	
Mouse experiments  262	
Fto deficient mice were a generous gift from Prof. Roger Cox (MRC Harwell, 263	
Oxford) and were genotyped as previously described (27).  This research is 264	
regulated under the Animals (Scientific Procedures) Act 1986 Amendment 265	
Regulations 2012 following ethical review by the University of Cambridge 266	
Animal Welfare and Ethical Review Body (AWERB).  Animals were kept under 267	
controlled temperature (22oC) and a 12-h light, 12-h dark schedule (lights on 268	
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07:00–19:00). Standard chow (Special Diet Services) and water were 269	
available ad libitum.   270	
For the vaginal opening study female Fto heterozygous mice (Fto+/-) (n=45) 271	
and their WT littermates (n=24) were taken from either a male Fto WT x 272	
female Fto+/- cross or a male Fto+/- x female Fto WT cross. From P21 (day of 273	
weaning) all female mice were weighed and visual examination of the vagina 274	
was carried out by placing the mouse on top of a cage lid and lifting the tail 275	
vertically away from the body.  No excessive force was involved.  First day of 276	
vaginal opening was recorded when a complete opening was observed.  277	
For all experiments, data are expressed as the mean ± SEM. To determine 278	
statistical significance, we used the unpaired t test (2-tailed) using SPSS 279	
Software (version 24). A p value of <0.05 was considered statistically 280	
significant.  281	
  282	
Results   283	
Variants in GWAS genes implicated in body mass were identified 284	
following exome sequencing in families with self-limited delayed 285	
puberty  286	
WES performed in the 67 largest and best phenotyped families from our 287	
cohort (160 individuals: a total of 125 individuals with DP, male=93, 288	
female=32; and 35 controls, male=13, female=22), identified 6,952,773 289	
variants after quality control (Figure 1). Filtering to identify high quality, rare, 290	
predicted deleterious variants not present in control subjects selected 12,371 291	
variants in 7,470 genes. Of these 7,470 genes, 238 were found to be in 292	
linkage disequilibrium with a GWAS locus for timing of puberty, and 5 of these 293	
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238 were genes implicated in body mass regulation or growth by pathway 294	
analysis. Of these 5 genes, 4 (GPD2, GHR, ESR1 and VDR) were found to 295	
have only variants that did not segregate with the DP trait in family members. 296	
The remaining candidate gene, FTO (Fat mass and obesity-associated 297	
protein, ENSG00000140718, gene identification number 79068), has been 298	
previously described in the literature as involved in pathways of energy 299	
homeostasis and growth (5), and is known to act as an Fe(II) 2-OG (2-300	
oxoglutarate) -dependent dioxygenase to repair alkylated DNA and RNA by 301	
demethylation (26). FTO contributes to the regulation of energy balance, and 302	
thus to the regulation of body size and fat accumulation.   303	
Two variants in FTO (NM_001080432.2: c.130C>G p.Leu44Val and 304	
NM_001080432.2: c.487G>A (rs145884431) p.Ala163Thr) were identified in 305	
three families from our cohort and found in one or fewer control subjects (rare 306	
variant burden testing adjusted p = 0.058). Both variants are rare (MAF < 307	
0.2%) heterozygous missense variants and predicted benign or tolerated by 308	
>2/5 prediction software tools.  309	
Families with potentially pathogenic FTO variants display autosomal 310	
dominant inheritance of DP phenotype and low body mass. 311	
The family identified with the p.Ala163Thr variant (family 1) and both of the 312	
families with the p.Leu44Val variant (families 2 and 3) displayed the typical 313	
autosomal inheritance pattern of the DP trait, with perfect segregation (Figure 314	
2, panel A). Affected individuals from family 1 with the p.Ala163Thr variant 315	
and from family 3 with the p.Leu44Val variant were particularly underweight in 316	
childhood, with the two probands from these families (individuals 1.III.2 and 317	
3.III.2) falling into the thinness grade 2 category(28) before puberty (Figure 2, 318	
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panels B and D). Although there was some variability in this phenotype, all 319	
family members carrying FTO variants had ISO-BMI values in the lower range 320	
(<23) (Figure 2 and Supplementary Fig. 1-3, Table 1). In addition, both of 321	
the probands from families 2 and 3 who carry the p.Leu44Val 322	
displayed faltering growth in early childhood. Both displayed significant 323	
deflection from previous height measurements in the 2 years following 324	
birth, as well as height significantly below target height in later adolescence 325	
associated with delayed pubertal growth (Figure 2, panels C and D) (22).   326	
In silico analysis of potential mutations 327	
We carried out in silico analysis using the solved structure of FTO (PDB 328	
identifier: 3lfm) to determine the possible pathogenicity of the identified 329	
variants. The hydrophobic residue Leucine 44 is part of a solvent-exposed 330	
alpha helix on the surface. Substitution with Valine is not predicted to alter the 331	
structure of FTO or interaction with iron molecules or DNA. However, L44 and 332	
other residues in the same solvent-exposed alpha helix form a motif 333	
(Supplementary Fig. 4 and 5), which is highly conserved across placental 334	
mammals but not reptiles, birds or fish (Supplementary Fig. 6). This motif 335	
(residues 36-48) forms a patch on the FTO protein surface (Supplementary 336	
Fig. 7). This may act as a mammal-specific interaction site (between FTO and 337	
another protein), required for FTO function for example in reproductive 338	
development. In this scenario, a small change in side chain volume, such as 339	
Leucine-to-Valine, may have a subtle effect in protein-protein interaction and 340	
lead to a change in FTO activity in vivo.  341	
Alanine 163 is a hydrophobic, not highly conserved residue (Supplementary 342	
Fig. 8, panel A). Alanine 163 is at the end of the H4 alpha helix and the 343	
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beginning of a long, disordered region (Supplementary Fig. 8, panel B), which 344	
connects helices H4 and H5 (Supplementary Fig. 8, panel C).  345	
FTO p.Leu44Val mutant protein displays reduced demethylase activity in 346	
vitro  347	
We carried out functional characterization of the identified mutant FTO 348	
proteins (p.Leu44Val and p.Ala163Thr) as compared to WT protein. A 349	
previously verified RNase-cleavage assay was used to measure the 350	
demethylation activity of FTO on 3-meU (26). Although kinetic activity of the 351	
mutant protein p.Ala163Thr did not vary from WT using this assay, mutant 352	
protein p.Leu44Val showed an approximately 20% lower kinetic activity than 353	
WT activity (Figure 3).    354	
FTO deficiency in vivo results in delayed vaginal opening in mice  355	
In order to examine the influence of FTO activity on pubertal timing in an in 356	
vivo model, we examined timing of puberty in mice deficient for FTO in the 357	
heterozygous state (Fto+/-), in keeping with the human genotype identified. Fto-358	
/- mice were not selected for these experiments because of their poor 359	
postnatal health (29). Fto+/- mice had significantly delayed timing of vaginal 360	
opening (VO) (mean postnatal day +/- SEM: 27.20 +/- 0.44 in wild-361	
type (n=24) vs 28.56 +/- 0.48 in Fto+/ mice (n=45), p =0.047), an event which 362	
reflects the pubertal rise in estradiol (30) (Figure 4). Mean body weight of 363	
the Fto+/ group was not significantly different to the WT mice (mean body 364	
weight (in g) +/- SEM: 11.64 +/- 0.21 in wild-type vs 11.45 +/- 0.14 365	
in Fto+/ mice, p=0.467) (Figure 5).  366	
Using simple linear modelling, Fto genotype of the pup (Het vs WT) explained 367	
approximately 3% of the total variation in timing of VO. Consideration of an 368	
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additional factor, maternal genotype, improved the model by increasing the 369	
significance of the association between pup genotype and timing of VO 370	
slightly (p=0.04), and accounted for 6% of the total variation in timing of VO. 371	
In contrast, paternal genotype decreased the significance and total variation 372	
accounted for by the model.  373	
  374	
Discussion  375	
Genome wide association studies of AAM in the general population have 376	
attempted to unravel the complex conundrum of which genetic 377	
factors influence the timing of puberty. Despite many loci being identified, 378	
clear evidence for the role of particular genes and pathways is for the most 379	
part lacking. Those genes lying within pathways of energy metabolism and 380	
growth appear promising, with the discovery of the role of Lin28B in C.elegans 381	
development(3) and the importance of leptin as a permissive signal in triggering 382	
the onset of puberty(9,31).  383	
The inheritance of DP is known to be under strong genetic influence with 384	
commonly an autosomal dominant inheritance pattern, and thus represents a 385	
useful basis for the investigation of puberty genetics. Notably, self-limited or 386	
constitutional DP is often associated with slow maturation throughout 387	
childhood, implicating growth and energy metabolism pathways in its 388	
pathogenesis. Previously, genes in such pathways identified through GWAS 389	
have not been screened in patients with DP.   390	
Our results have identified variants in FTO as a potential contributory factor in 391	
the development of self-limited DP in three pedigrees from our large cohort of 392	
patients with familial DP. FTO (fat mass and obesity associated gene) was the 393	
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first obesity-susceptibility gene identified through GWAS and continues to be 394	
the locus with the largest effect on body mass index (BMI) and obesity risk (10). 395	
Those DP patients identified with FTO variants from our study showed 396	
reductions in body mass. The FTO variants carried by our DP patients may 397	
result in reduced fat mass, which would in turn contribute to a delay in the 398	
timing of pubertal onset. This delay may be mediated directly through reduced 399	
leptin levels. Although we do not routinely measure leptin levels in DP 400	
patients, leptin levels have been shown to be significantly lower in pubertal-401	
age patients with self-limited DP(32).   402	
Notably, in an in vivo model Fto+/- mice had a significantly delayed onset of 403	
puberty as compared to WT mice. In the 7 days preceding puberty onset, 404	
however, body weight was not significantly different between the two pup 405	
genotype groups. Previous studies have demonstrated that Fto-/- mice show a 406	
30-40% reduction in body weight by 6 weeks of age (29) and that transgenic 407	
mice with additional copies of Fto show a dose-dependent increase in body 408	
and fat mass (33). However, the relationship between FTO genotype, fat mass 409	
and leptin levels remains somewhat unclear. Fto deficient mice do become 410	
obese when subjected to a high fat diet, although they remain sensitive to the 411	
anorexigenic effects of leptin (29,34).  412	
Moreover, it is possible that FTO gene dosage may have an effect on energy 413	
homeostasis independent of effects on fat mass (33),, including on the balance 414	
between catabolic and anabolic pathways (35). FTO has been identified as an 415	
amino acid sensor acting, via mTOR, to influence appropriate levels of 416	
development and translation(36). FTO is expressed within the hypothalamus in 417	
several sites critical for energy balance, including in the arcuate nucleus 418	
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within proopiomelanocortin (POMC) neurons(37,38). In one study Fto levels in 419	
the arcuate nuclei of fasted mice fell by up to 60%, and this was not rescued 420	
by leptin administration. Other studies have shown conflicting results in the 421	
effects on Fto mRNA levels of fasting, depending on whether whole 422	
hypothalamus or arcuate nucleus were studied and on the length of fast (38). 423	
However, Fto-/- mice display blunted starvation-induced Npy mRNA 424	
induction(29). More recent studies have suggested that Fto may influence the 425	
metabolic outcomes of a high fat diet via hypothalamic signaling pathways 426	
acting independently of body weight (34). Mutations in FTO, including those 427	
with greatly reduced demethylase activity (e.g. pR316Q, Figure 3), have been 428	
identified in human subjects associated with both lean and obese phenotypes 429	
(25). We were not able in our study to identify the mechanism by which the 430	
p.Ala163Thr variant might affect protein function; although no reduction in 431	
demethylation activity was demonstrated it is possible that this variant may 432	
produce a deleterious effect by another route, for example defects in post-433	
translational modification or protein degradation.  434	
Thus, FTO may be important for signaling energy sufficiency 435	
and the ‘healthy energy balance’ required for pubertal onset. Our in 436	
silico analysis suggests that the p.Leu44Val mutation we have identified may 437	
represent a mammal-specific interaction site between FTO and another 438	
protein (or DNA), important for FTO function in terms of reproductive 439	
development. Moreover, maternal genotype may contribute to pubertal timing, 440	
as demonstrated from our Fto+/- mice data. A reproductive phenotype present 441	
in Fto heterozygote mothers could expose pups to a suboptimal environment 442	
that could influence their puberty timing. 443	
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Finally, our finding of maturational delay in growth in early childhood in the 444	
two probands with p.Leu44Val mutation is of interest. Constitutional delay in 445	
growth is seen in a subset of patients with DP, and our findings implicate 446	
mutations in energy pathway genes in the pathogenesis of patients with such 447	
a phenotype.     448	
Overall, our discovery of two rare variants in FTO associated with self-limited 449	
DP in our large familial cohort, and of delayed vaginal opening in FTO-450	
deficient mice, provides evidence that perturbations in pathways of energy 451	
homeostasis and growth may potentially produce a phenotype of DP. We note 452	
that despite this extensive analysis, only three of 67 probands were identified 453	
with potentially pathogenic variants in such pathways, highlighting the high 454	
degree of heterogeneity in the genetic basis of self-limited DP. These findings 455	
merit further exploration in our own cohort and in other populations, including 456	
sub-group analysis of DP patients with low BMI from early childhood. 457	
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Figure Legends: 676	
  677	
Figure 1 – Flowchart of WES (whole exome sequencing) filtering 678	
strategy to identify candidate genes.  679	
Whole exome sequencing was initially performed on DNA extracted from 680	
peripheral blood leukocytes of 160 individuals from the 67 most extensive 681	
families from our cohort (125 with DP and 35 controls), with exome capture on 682	
a Nimblegen V2 or Agilent V5 platform and sequencing on the 683	
Illumina Hiseq 2000. The exome sequences were aligned to the UCSC hg19 684	
reference genome. Picard tools and the genome analysis toolkit were used to 685	
mark PCR duplicates, realign around indels, recalibrate quality scores and call 686	
variants. Variants were then analyzed further and filtered for potential causal 687	
variants using filters for quality control, predicted functional annotation, minor 688	
allele frequency (MAF), segregation with trait and GWAS relevance (See 689	
methods for further information on filtering criteria). Targeted exome 690	
sequencing using a Fluidigm array of a candidate gene identified post-filtering 691	
was then performed in a further 42 families from the same cohort (288 692	
individuals, 178 with DP and 110 controls). Variants post targeted re-693	
sequencing were filtered using the same criteria as the whole exome 694	
sequencing data. Functional annotation of the variants as described 695	
elsewhere in methods. DP – delayed puberty.   696	
 697	
Figure 2 – Pedigrees and auxological data of the families with potentially 698	
pathogenic FTO variants   699	
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Panel A: Squares indicate male family members, circles female family 700	
members. Black symbols represent clinically affected, grey represent 701	
unknown phenotype, clear symbols represent unaffected individuals. The 702	
arrow with ‘P’ indicates the proband in each family and ‘us’ indicates un-703	
sequenced due to lack of DNA from that individual. The mutation in each 704	
family is given next to the family number; a horizontal black line above an 705	
individual’s symbol indicates they are heterozygous for the variant as 706	
confirmed by either whole exome sequencing or Fluidigm array, and verified 707	
by Sanger sequencing.  A red dot indicates the individual was underweight 708	
(thinness grade 2 or more significant) and ‘?’ indicates that BMI information 709	
for that individual is not available. 710	
Panels B-D: BMI and height standard deviation score (SDS) charts for 711	
the probands of each of the three pedigrees (family 1.III.2, family 2.III.5 and 712	
family 3.III.2). Underweight values are shown in red, green dots indicate a 713	
significant deflection from previous height measurements and orange dots 714	
indicate significant deflection from target height. Normal values, based on 715	
data from >70,000 healthy Finnish children, have been previously published 716	
(22).  717	
  718	
 Figure 3 – Demethylation assay assessing kinetic activity of mutant 719	
versus wild type FTO proteins.   720	
FTO activity is proportional to the concentration present in the reaction. 721	
Demethylase activity is likely to be related to the ability of FTO to function as a 722	
sensor for cellular metabolism (36). The R316Q mutant is enzymatically dead 723	
across all concentrations tested. The A163T and L44V mutants showed 724	
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demethylase activity towards methylated-uridine in a dose-dependent manner 725	
but with different affinities. WT – wild-type  726	
 727	
Figure 4 – Timing of vaginal opening in wild-type (WT) and FTO+/-728	
heterozygous (Het) mice.   729	
Cumulative percentages of mice displaying vaginal opening by postnatal day 730	
are shown for WT and FTO+/- mice. WT mice n=24, FTO+/- n=45; p <0.05 by 731	
un-paired t test.  732	
 733	
 Figure 5 – Mean body weight (g) for wild type (WT) and Fto+/- (Het) mice 734	
in 7 days prior to vaginal opening   735	
Mean body weight (g) +/- SEM: 11.64 +/- 0.21 in wild-type (n=24) vs 11.45 +/- 736	
0.14 in Fto+/ mice (n=45), p=0.467 by un-paired t test. Error bars show SEM 737	
for each group each day.  738	
 739	
  740	
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Case Sex Amino acid 
alteration 
Height 
SDS at 
age 4 yrs 
Height SDS 
at age 8/9 
yrs 
Height SDS 
at age 18 
yrs 
ISO-BMI 
at 18 yrs 
1.II.1 M p.Ala163Thr - 1.1 1.7 16.9 
1.III.2 
(P) 
M p.Ala163Thr 1.1 0.5 1.1 17.1 
1.III.1 F p.Ala163Thr 0.9 1.0 1.1 17.3 
1.II.5 M p.Ala163Thr -1.0 -1.0 -0.4 - 
2.III.5 
(P) 
M p.Leu44Val -0.9 -1.4 -1.5 18.8 
2.III.6 M p.Leu44Val -1.1 -1.3 - - 
2.II.2 M p.Leu44Val - -0.8 -0.8 20.5 
2.III.1 M p.Leu44Val 0 -1.4 - - 
3.II.2 M p.Leu44Val - -1.0 -0.9 18.6 
3.III.2 
(P) 
M p.Leu44Val -0.9 -1.1 -1.3 18.7 
3.II.3 M p.Leu44Val  -0.4 -0.1 22.7 
3.III.3 M p.Leu44Val -0.1 0.2 0.5 17.8 
 741	
Table 1 – Clinical data of probands with FTO variants 742	
Height is expressed in s.d. score (SDS) for national reference data for Finland 743	
at 4 years of age and at either 8 years for girls or 9 years for boys. Normal 744	
limits: delta HSDS <1.21, distance to target height at 4 yrs <1.76, distance to 745	
target height at 8/9 yrs <1.72(22). P – proband. 746	
 747	
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 748	
  749	
Figure 1 – Flowchart of WES (whole exome sequencing) filtering 750	
strategy to identify candidate genes.  751	
 752	
 753	
160 individuals (67 families, 125 with self-limited DP & 35 controls) 
6,952,773 variants 
627,802 variants 
12371 variants 
434 variants in 283 genes prioritised 
1 gene in additional 288 individuals (42 
families, 178 with DP, 110 unaffected) 
1 gene (FTO) with 2 variants not present in 
controls 
1 gene (FTO) with 1 pathogenic variant in 2 
families validated 
45509 variants 
Whole exome 
sequencing!
Quality control 
Predicted function 
MAF < 1% 
Genetic Analysis 
20057  variants  
Targeted exome 
sequencing !
Sanger seq for within 
pedigree segregation  
Functional annotation of 
variants 
GWAS relevance!
4 genes (GPD2, 
GHR, ESR1, VDR) 
with variants not 
segregating 
Body mass relevance 
5 variants in 5 genes prioritised 
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 754	
 755	
Figure 2 – Pedigrees and auxological data of the families with potentially 756	
pathogenic FTO variants   757	
  758	
  759	
  760	
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 761	
 762	
Figure 3 – Demethylation assay assessing kinetic activity of mutant 763	
versus wild type FTO proteins.   764	
  765	
  766	
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 768	
Figure 4 – Timing of vaginal opening in wild-type (WT) and FTO+/-769	
 heterozygous (Het) mice.   770	
 771	
  772	
  773	
  774	
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 775	
 776	
Figure 5 – Mean body weight (g) for wild type (WT) and Fto+/- (Het) mice in 777	
7 days prior to vaginal opening   778	
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Supplementary Methods:  
Patient Details 
For family members diagnosis of DP was based on PHV occurring 1.5 SD 
beyond the mean, i.e. age at takeoff exceeding 12.9 and 11.3 yr, or age 
at PHV exceeding 14.8 and 12.8 yr in males and females. This 1.5SD cutoff 
has sensitivity of 98% in identifying boys with Tanner stages G2 later than 
14.0 years and sensitivity of 97% in identifying girls with Tanner stage B2 later 
than 13.0 years. 
Genetic Analysis  
Genetic analysis was performed in 160 individuals from the 67 most extensive 
families from our cohort with DP. These included 67 probands (male n=57, 
female n=10), 58 affected family members (male n=36, female n=22) and 35 
unaffected family members (male, n=13, female n=22). Whole exome 
sequencing (WES) was performed on DNA extracted from peripheral blood 
leukocytes, using a Nimblegen V2 or Agilent V5 platform and Illumina HiSeq 
2000 sequencing. The exome sequences were aligned to the UCSC hg19 
reference genome. Picard tools and the genome analysis toolkit were used to 
mark PCR duplicates, realign around indels, recalibrate quality scores and call 
variants.  
Variants were analyzed and filtered for potential causal variants in Ingenuity 
Variant Analysis (Qiagen) using filters for quality control, predicted functional 
annotation, minor allele frequency (MAF), and GWAS relevance (Figure 1). 
Quality control included thresholds for call quality, read depth and upstream 
pipeline filtering. Predicted functional annotation involved prioritizing 
nonsense, exonic missense, splice site variants, structural or promoter 
	 3	
changes, or variants deleterious to a microRNA. Filtering by MAF entailed 
including those variants with minor allele frequency (MAF) <1% in the 1000 
Genomes database, the NHLBI exome variant server, and ExAC and 
gnoMAD databases. GWAS relevance filtering allowed identification of those 
remaining variants that lay within genes in linkage disequilibrium with 106 
GWAS loci associated with AAM1. All genes in linkage disequilibrium with 
these GWAS AAM loci (using inclusive limits: D’ > 0.8; r2: no limit) were 
selected using the Broad institute SNAP tool (SNP annotation and proxy 
search). Linkage disequilibrium data was calculated using Haploview 4.0, 
based on phased genotype data from the International HapMap Project and 
the 1000 Genomes Project. A total of 760 genes were selected using this 
SNAP tool, and ‘GWAS relevance filtering’ allowed identification of those 
remaining variants that lay within these 760 genes 2. Filters for genes 
implicated in body mass regulation were applied using a biological context 
filter with pathway analysis. Variants were then filtered for segregation with 
trait: variants present in ≥ n-1 affected individuals (where n = number of 
affected individuals in a given pedigree) and not present in more than one 
unaffected individual being retained. Family members were screened using 
conventional Sanger sequencing.  
Targeted exome sequencing using a Fluidigm array of the remaining 
candidate gene identified post-filtering was then performed in a further 42 
families from our cohort (288 individuals, 178 with DP; male=106, female=69 
and 110 controls; male=55, female=58, Figure 1). Variants post targeted re-
sequencing were filtered using the same criteria as the WES data: quality 
	 4	
control, predicted functional annotation, minor allele frequency and 
segregation with trait.  
Whole gene rare variant burden testing was performed post sequencing. 
Fisher’s exact test was used to compare the prevalence of deleterious 
variants in our cohort with the Finnish population, using the ExAC Browser 
(Exome Aggregation Consortium (ExAC), Cambridge, 
MA: http://exac.broadinstitute.org, accessed September 2015). All variants 
from the ExAC database with minor allele frequency <1%, predicted to be 
deleterious by Polyphen-2 3 or SIFT 4, were included in the analysis. A 
multiple comparison adjustment was applied post hoc using the Benjamini & 
Hochberg method 5, as detailed in 6. Variants were confirmed via Sanger 
sequencing.  
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Supplementary Figures 
 
 
 
Supplementary Fig. 1 - Auxological data of the family members from Family 1 
with potentially pathogenic FTO variant. 
BMI and height standard deviation score (SDS) charts for the family members with 
FTO variant. Underweight values are shown in red, green dots indicate a significant 
deflection from previous height measurements and orange dots indicate significant 
deflection from target height. Normal values, based on data from >70,000 healthy 
Finnish children, have been previously published 7.  
 
 
 
	 6	
 
 
 
Supplementary Fig. 2 - Auxological data of the family members from Family 2 
with potentially pathogenic FTO variant. 
BMI and height standard deviation score (SDS) charts for the family members with 
FTO variant. Underweight values are shown in red, green dots indicate a significant 
deflection from previous height measurements and orange dots indicate significant 
deflection from target height. Normal values, based on data from >70,000 healthy 
Finnish children, have been previously published 7.  
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Supplementary Fig. 3 - Auxological data of the family members from Family 3 
with potentially pathogenic FTO variant. 
BMI and height standard deviation score (SDS) charts for the family members with 
FTO variant. Underweight values are shown in red, green dots indicate a significant 
deflection from previous height measurements and orange dots indicate significant 
deflection from target height. Normal values, based on data from >70,000 healthy 
Finnish children, have been previously published 7.  
	 8	
 
 
 
 
 
 
Supplementary Fig. 4 - Surface representation of FTO (here presented in grey) 
bound to 3--‐methylthymidine (in yellow). Leucine 44 is presented in blue. 
 
 
 
 
 
 
 
Supplementary Fig. 5 - 3D structure of FTO bound to 3--‐methylthymidine and 
iron (PDB 3flm)  
FTO N--‐terminal domain is presented in grey and the C--‐terminal domain in orange. 
Dna is presented as yellow spheres, iron as a blue sphere. Deleterious mutations 
p.R96M or W, p. Y108A, p.F114D, p.E234P, p.C392D are presented as red spheres. 
p.L44V is presented in blue. 
p.L44V&
3(methylthymidine&
p.L44V&
3(methylthymidine&
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Supplementary Fig. 6 – Multiple sequence alignment between human FTO and 
its orthologues.  
Orthologous sequences from other species were retrieved from Ensembl. Species 
are classified in “Placental mammals”, “Birds & Reptiles” and “Fish” according to 
Ensembl classification. For each species, FTO Uniprot accession number (in blue) 
and entry name (in black) are presented at the beginning of the row. The position of 
deleterious mutations on the human FTO sequence is indicated by a red arrow. L44 
and other surrounding residues part of the same alpha helix form a motif, which is 
highly conserved across placental mammals but not in reptiles, birds and fish. 
 
 
 
 
Supplementary Fig. 7 – Tertiary structure of FTO local to L44 residue. Residue 
L44 is presented in blue and other residues located on the same alpha helix and 
conserved across placental mammals are presented in green. FTO structure is 
shown as cartoon on the left and as surface on the right. 3--‐methylthymidine is 
presented as yellow spheres in the cartoon representation. 
Placental(
mammals(
Birds(&(
Rep2les(
Fish(
p.L44V(
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Supplementary Fig. 8 - p.A163T sequence and structural analysis.  
Panel A: a multiple sequence alignment shows that alanine at position 163 is not 
conserved. Panel B: the position of Ala163 (indicated by a red arrow) is presented in 
relation to FTO secondary structure (H, alpha helix; C, residues that are not part of 
an alpha helix or a beta strand). Residues predicted to be disordered are indicated 
with an asterisk. Panel C: FTO tertiary structure. Ala163 (presented in red) is at the 
end of FTO alpha helix H4 and is not predicted to disrupt FTO function. FTO 
structure is visualized using visualisation program (http://www.pymol.org/). 
 
 
 
Gene Symbol 
FTO GNPDA2 LEKR1 
SEC16B BDNF DLK1 
TMEM18 LIN28B LEPR-
LEPROT 
NEGR1 SIX6  
TNN13K CENPW-NCO7  
 
 
Supplementary Table 1 – Genes involved in energy metabolism and growth 
pathways implicated in the timing of puberty in the general population from 
genome wide association studies (adapted from Perry et al 1). 
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